For research use only. Not for therapeutic Use.
PARP-1-IN-4 is a PARP-1 inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC50 value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma[1].
PARP-1-IN-4 has inhibitory activity against PARP-1 with IC50 value of 302 μM[1].
PARP-1-IN-4 (0.1, 1 and 10 μM; 24h and 48h) has cytotoxicity activity against A549 cells[1].
PARP-1-IN-4 (1 μM; 24h) exhibits a significant increase in the expression levels of caspase-3 and caspase-9protein[1].
| Catalog Number | I041145 |
| CAS Number | 684234-56-8 |
| Synonyms | N-(4-chlorophenyl)-2-[4-(4-chlorophenyl)-1-oxophthalazin-2-yl]acetamide |
| Molecular Formula | C22H15Cl2N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H15Cl2N3O2/c23-15-7-5-14(6-8-15)21-18-3-1-2-4-19(18)22(29)27(26-21)13-20(28)25-17-11-9-16(24)10-12-17/h1-12H,13H2,(H,25,28) |
| InChIKey | ZYDMHJZNLFTYOR-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C(=NN(C2=O)CC(=O)NC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl |
| Reference | [1]. Almahli H, et al. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. Bioorg Chem. 2018;77:443-456. |
